Translational research aims to bridge the vast amount of disease knowledge generated at the life science research bench with an expected benefit at the bedside in the clinical domain. But given the number of studies performed, papers published, and trials run – compared with the number of new treatment options reaching patients – it’s apparent that predictive value at the bedside is lagging. The translational research process is commonly viewed as unidirectional and unproductive, which points to an opportunity to remodel our approach.
During this panel discussion we will explore:
– Lack of transparency
– Reshaping the bench-to-bedside process
– Incorporating real-world data sources into translational research study designs
– Developing and improving patient-centricity
Panelists to be announced